Technology | May 04, 2012

Angioslide Announces FDA 510(K) Clearance of Proteus Below-the-Knee Device

May 4, 2012 - Angioslide Ltd., a provider of embolic capture angioplasty solutions, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new 3x100 mm Proteus device for treating peripheral artery disease in below-the-knee (BTK) vasculature. The new 3/100 mm device accommodates 0.014-inch guidewires, which significantly broaden the potential use of Proteus technology.

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of built-in embolic capture. Proteus is a competitive percutaneous transluminal angioplasty (PTA) balloon with features similar to leading PTA balloons (deflation time, pushability, crossing profile). Then, during deflation, the Proteus captures and retrieves potentially harmful embolic material. The capture of embolic material is enabled by the inward folding of the balloon, which creates a low-pressure cavity. The negative pressure in this cavity generates an aspiration effect, pulling embolic material into the cavity. When retrieved through the sheath, Proteus removes the captured material from the body.

BTK interventions are often characterized by patients with long and diffuse lesions, diabetic foot ulcers and/or critical limbs ischemia. Proteus 3x100 offers physicians, for the first time, the ability to capture and remove embolic material with a single device during these challenging interventions.

“Introduction of the new dedicated, BTK, low-profile 0.014-inch Proteus platform supports Angioslide's continuing commitment to improve procedure outcomes. Distal embolic complications in this compromised group of patients further risk blood flow to the foot. Proteus will become a necessary device in the 'tool-box' of physicians practicing "endovascular-first" approach,” said Lihu Avitov, Angioslide CEO.

For more information: www.angioslide.com

Related Content

Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init